Discontinuation of immune checkpoint inhibitors for reasons other than disease progression and the impact on relapse and survival of advanced melanoma patients. A systematic review and meta-analysis.

Fiche publication

Date publication

janvier 2025

Journal

Frontiers in immunology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr AMARAL Teresa Maria

Tous les auteurs :
Lallas K, Chatziioannou E, Durak D, Frey G, Serna-Higuita LM, Rasch ML, Kyrgidis A, Timotheadou E, Apalla Z, Leiter U, Flatz L, Lallas A, Amaral T

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/39958328

Résumé

Despite durable responses achieved with Immune Checkpoint Inhibitors (ICIs), data about optimal duration of treatment, especially in the context of adverse events, remain scarce.